CD4 and asthma: Accordingly, miR-155 was described to stimulate the TH2 response and mucus hypersecretion by directly targeting sphingosine-1-phosphate receptor 1 and cytotoxic T lymphocyte–associated antigen 4 in CD4+ cells in experimental models of asthma [30,31].